Diabetes Studies

1. The pharmacokinetics and the pharmacodynamics of once a day and twice a day dosing of XXX in non insulin dependent diabetes mellitus (NIDDM) subjects.
2. A randomized double-blind, placebo-controlled study of the efficacy and safety of XXX in the treatment of type II diabetic patients (NIDDM).
3. A Randomized Parallel, Double-Blind, Placebo-Controlled Study of the Efficacy, Timing, and Safety of XXX in the Treatment of Type II Diabetic Patients (Sulfonylurea- Failures).
4. A Randomized, Double-Blind, Placebo Controlled Six Month Safety and Efficacy Trial of 7.5, 15, 30, 45 mg QD of XXX in Type II Diabetes Mellitus Patients (Non Insulin Dependent Mellitus, NIDDM).
5. An Open-Label, Long-Term Tolerability Study of XXX in Type II Diabetes Mellitus Patients (Non-Insulin Dependent Diabetes Mellitus, NIDDM).
6. A Double-Blind, Placebo Controlled, Randomized Study of the Safety and Efficacy of a Combination of Sulfonylurea and Two Doses of XXX (15 or 30 mg) in the Treatment of Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM).
7. A Double-Blind, Placebo Controlled, Randomized Study of the Safety and Efficacy of a Combination of Insulin and Two Doses of XXX (15 or 30 mg) in the Treatment of Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM).
8. A Double-Blind, Placebo Controlled, Randomized Study of the Safety and Efficacy of a Combination of Metformin and 30 mgXXX in the Treatment of Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM).
9. A Randomized, Placebo-Controlled, Parallel Group, Multiple Dose Study of the Effects of XXX and XXX in Non-Insulin Dependent Diabetes Patients.
10. A Double-Blind, Randomized Study of the Safety and Efficacy of a Combination of Sulfonylurea and 45 mg of XXX Compared to a Combination of Sulfonylurea and 30 mg of XXX in the Treatment of Patients with Type 2 (Non-Insulin Dependent) Diabetes Mellitus.
11. Comparative Pharmacokinetics and Pharmacodynamics of XXX in Hypertensive Patients with and without Type II Diabetes Mellitus.
12. Placebo-Controlled, Ascending multiple-dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of XXXX in type II diabetic subjects.
13. A Randomized, double-blind multicenter study comparing the effects of XXX and XXX on Glycemic control in hypertensive patients with type II Diabetes mellitus.
14. A Phase II, 12-week, randomized, double-blind, four-arm, placebo-controlled, dose-ranging study for safety of efficacy of XXX in type II diabetic subjects.